Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-001 in wAMD
NCT06839339Phase 2Not yet recruiting
- Sponsor
- Anlong Bio
- Start
- Feb 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AL001 in exudative macular degeneration (3 arms), sponsored by Anlong Bio. Primary endpoint: Best Corrected Visual Acuity at Week 24. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
AL001
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06839339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839339.